biota wins a us patent for treatment of cancer, page-126

I disagree with everyone, I think this is not a material event for BTA. In contrast, it is a material event for Biocryst who have a clinical trial planned dependent on their patient application been granted.

Does anyone know:
1. How many patients BTA has in the US?;
2. How many patients relate to HCV?;
3. Where does this patient fit in with BTA future plans for HCV?
4. Where does this patient fit in with prior licencing agreements Biota has signed wrt HCV?

Rather, I think BTA should give a briefing on the status on its HCV program, current licencing agreements still in place, planned future work with licencees and on BTA's own behalf, including mention of any patients it has and how significant is this particular patient in the overall scheme of things.


Regards

SP